Susan M. Domchek
University of Pennsylvania
535 Papers
2.1K Citations
Susan M. Domchek is an academic researcher from University of Pennsylvania. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 83, co-authored 439 publications. Previous affiliations of Susan M. Domchek include Brigham and Women's Hospital & Cancer Council Victoria.
Chat about Author
Papers
Phase II study of olaparib (O) and durvalumab (D) (MEDIOLA): Updated results in patients (pts) with germline BRCA-mutated (gBRCAm) metastatic breast cancer (MBC)
Susan M. Domchek,Sophie Postel-Vinay,S.-A. Im,Young-Ae Park,J.-P. Delord,Antoine Italiano,Jérôme Alexandre,Benoit You,S Bastian,Matthew G Krebs,Ding Wang,S. Waqar,M. Lanasa,Helen K. Angell,Zhongwu Lai,C. Gresty,L Opincar,P. Herbolsheimer,Bella Kaufman +18 more
TL;DR: The data suggest that pts with fewer prior lines of chemotherapy (0/1) had higher ORR, longer mDoR, mPFS and mOS than those with 2 prior lines.
51
Stumbling Blocks on the Path to Personalized Medicine in Breast Cancer: The Case of PARP Inhibitors for BRCA1/2-Associated Cancers
TL;DR: A brief review of current developments concerning PARP inhibitors in BRCA-associated cancers is provided and concerns about challenges to further development are expressed.
51
Retrospective Survival Analysis of Patients With Advanced Pancreatic Ductal Adenocarcinoma and Germline BRCA or PALB2 Mutations
Kim A. Reiss,Shun Yu,Renae Judy,Heather Symecko,Katherine L. Nathanson,Susan M. Domchek +5 more
- 19 Jan 2018
TL;DR: Platinum-based therapy may confer a survival benefit in patients with advanced PDAC who carry a deleterious germline BRCA1, BRCa2, or PALB2 mutation.
50
Predicting BRCA1 and BRCA2 gene mutation carriers: comparison of PENN II model to previous study.
Noralane M. Lindor,Kiley J. Johnson,Hayden Harvey,V. Shane Pankratz,Susan M. Domchek,Katherine S. Hunt,Marcia Wilson,M. Cathie Smith,Fergus J. Couch +8 more
TL;DR: PENN II model for BRCA1/2 prediction performed well in this population with higher AUC compared with the experience using four other models, and the ease of use of the PENNII model is compatible with busy clinical practices.
Association of the variants CASP8 D302H and CASP10 V410I with breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers.
Christoph Engel,Beatrix Versmold,Barbara Wappenschmidt,Jacques Simard,Douglas F. Easton,Susan Peock,Margaret Cook,Clare Oliver,Debra Frost,Rebecca Mayes,D. Gareth Evans,Rosalind A. Eeles,Joan Paterson,Carole Brewer,Lesley McGuffog,Antonis C. Antoniou,Dominique Stoppa-Lyonnet,Olga M. Sinilnikova,Laure Barjhoux,Marc Frenay,Cécile Michel,Dominique Leroux,Hélène Dreyfus,Christine Toulas,Laurence Gladieff,Nancy Uhrhammer,Yves-Jean Bignon,Alfons Meindl,Norbert Arnold,Raymonda Varon-Mateeva,Dieter Niederacher,Sabine Preisler-Adams,Karin Kast,Helmut Deissler,Christian Sutter,Dorothea Gadzicki,Georgia Chenevix-Trench,Amanda B. Spurdle,Xiaoqing Chen,Jonathan Beesley,Håkan Olsson,Ulf Kristoffersson,Hans Ehrencrona,Annelie Liljegren,Rob B. van der Luijt,Theo A. M. van Os,Flora E. van Leeuwen,Susan M. Domchek,Timothy R. Rebbeck,Katherine L. Nathanson,Ana Osorio,Teresa Ramón y Cajal,Irene Konstantopoulou,Javier Benitez,Eitan Friedman,Bella Kaufman,Yael Laitman,Phuong L. Mai,Mark H. Greene,Heli Nevanlinna,Kristiina Aittomäki,Csilla Szabo,Trinidad Caldés,Fergus J. Couch,Irene L. Andrulis,Andrew K. Godwin,Ute Hamann,Rita K. Schmutzler +67 more
TL;DR: The combined application of these and other recently identified genetic risk modifiers could in the future allow better individual risk calculation and could aid in the individualized counseling and decision making with respect to preventive options in BRCA1 mutation carriers.